REDSENSE MEDICAL AB
NNGM:REDS3.84
SEK
+0.43
(+12.61%)
ISIN
SE0006965158
Return %
Stock
S&P 500
1Y
-12.73
14.20
3Y
-59.06
81.12
5Y
-83.30
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Sebastien Bollue
- Full Time Employees
- 4
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Maskinvägen 1 Halmstad Sweden 227 30
- IPO Date
- Jun 17, 2015
- Website
- redsensemedical.com
- Similar Companies
- Business
- GPX Medical AB (publ) (ticker: GPXMED.ST), a medical technology company focused on neonatal intensive care, develops and commercializes NEOLA, a non-invasive medical device that provides continuous lung monitoring through real-time measurement of lung volume changes and oxygen gas concentration using laser spectroscopy technology; this enables instant detection and alerts for life-threatening complications in preterm infants, improving care outcomes and reducing risks of long-term disabilities. The company targets neonatal intensive care units in key markets including the United States, Europe (such as Germany, France, and the United Kingdom), and Australia, operating within the medtech segment for pediatric respiratory monitoring with a razor-razorblade business model involving device sales and recurring sensor disposables. Founded in 2016 and headquartered in Lund, Sweden, GPX Medical is a subsidiary of Gasporox AB and was formerly known as GPX Medical before changing its name to Neola Medical AB in June 2022, with ongoing operations under the GPXMED.ST ticker. Recent developments include attainment of an IECEE CB certificate from FORCE Technology for international safety and electromagnetic compatibility standards in 2024, ISO 13485 certification for its quality management system, selection as a Stanford Impact1 company supported by the FDA to accelerate pediatric innovation to market, and progress toward U.S. market approval as highlighted in the CEO's Autumn 2024 investor letter, alongside securing exclusive distribution rights in Australia through BTC in 2021 with anticipated CE marking in 2023. The company continues to advance regulatory milestones for commercial launch, emphasizing GASMAS technology showcases and strategic steps for neonatal lung monitoring deployment.